Background-Major bleeding has received increasing attention as a target for quality improvement in care of patients with acute myocardial infarction. However, little is known about variation in bleeding across hospitals and whether variation is attributable to quality of hospital care, treatments, or case mix. Methods and Results-We characterized hospital variation in major bleeding events (an absolute hemoglobin drop ≥4 g/ dL, intracranial hemorrhage, retroperitoneal bleed, or transfusion) among 99 200 patients with non-ST-segment elevation myocardial infarction in the National Cardiovascular Data Registry (NCDR) Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines (ACTIOM Registry-GWTG) between January 2007 and June 2010. A total of 9566 (9.6%) patients experienced a major bleeding event during hospitalization. The median of the estimated distribution of major bleeding rates across hospitals was 9.4% (interquartile range, 7.5%-11.7%), with some hospitals having bleeding rates >2.3 times higher than others (10th-90th percentile, 6.1%-14.2%). Multivariable hierarchical models revealed that differences in case mix explained 19.2% of the hospital variation in bleeding complications, where anticoagulation and antiplatelet strategies explained an incremental 9.9% and 6.8%, respectively. Together, 32.3% of hospital variation in major bleeding rates was attributable to differences in patient case mix and identifiable differences in treatment strategies in patients with non-ST-segment elevation myocardial infarction. Conclusions-In-hospital major bleeding rates varied widely across hospitals. Although patient factors and treatments explained less than one third of hospital-level variation, ≈70% of bleeding variation remains after adjustment. A better understanding of causes for substantial hospital-level bleeding variations is needed to help target high-risk patients or practices and to optimize care. (Circ Cardiovasc Qual Outcomes. 2014;7:236-243.) Key Words: hemorrhage ◼ quality of health care
G uideline-recommended antiplatelet, anticoagulation, and catheter-based interventions play a pivotal role in the management of acute myocardial infarction, but these therapies can also increase the likelihood of bleeding, especially among high-risk patients. [1] [2] [3] [4] Given the variations in patient risk profiles and regional patterns of care, there can be an expected variation in bleeding among hospitals. Hospitals that provide care to high-risk patients or provide more invasive care have a higher incidence of bleeding complications compared with hospitals with a lower-risk patient population or those that provide more conservative care. 5 Further variation in hospital bleeding rates may also be attributable to modifiable issues in care processes (ie, selection of antithrombotic and antiplatelet agents, appropriate dosing of those medications especially when renal adjustment is required, choice of access site for cardiac catheterization, and use of bleeding avoidance therapies) that could be targets for quality improvement. Although some hospital variability in rates of bleeding complications is expected, the extent to which meaningful variation remains after accounting for patient characteristics, guideline-recommended care, or chance variation is unknown. Therefore, we sought to characterize the hospital variation in major bleeding rates. More importantly, we hoped to determine the degree to which patient case mix and in-hospital treatment factors (anticoagulant and antiplatelet strategies, use of catheter-based procedures, etc) influence hospital bleeding variability. Understanding the reasons for variability among hospital bleeding rates would provide insight into key determinants of bleeding complications and further inform the utility of reported rates of major bleeding complications as a measure of quality and as a target for quality improvement.
Methods

Study Population
The National Cardiovascular Data Registry (NCDR) Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines (ACTION Registry-GWTG) is a nationwide, ongoing, voluntary quality improvement registry sponsored by the American College of Cardiology (ACC) and the American Heart Association (AHA) that focuses exclusively on patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). Details of the design and conduct of the registry have been previously described. 6, 7 Standardized data collection includes patient demographics, medical history, and in-hospital clinical processes of care and outcomes. The validity of data collection in the ACTION Registry-GWTG has been reported. 6 Definitions for the data elements are available at https://www.ncdr.com/webncdr/action/home/datacollection. The Duke Clinical Research Institute serves as the data coordinating center to analyze deidentified data for research purposes. The institutional review board of each reporting hospital approved participation in the ACTION Registry-GWTG. Because all data are abstracted retrospectively and anonymously without unique patient identifiers, institutional review boards, by policy, waive the need for patient informed consent.
Because of different treatment strategies for STEMI and NSTEMI, we chose specifically to study 124 918 NSTEMI patients in the ACTION Registry-GWTG between January 1, 2007, and June 30, 2010 ( Figure 1 ). We sequentially excluded patients in centers utilizing a limited version of the data collection form because details of acute medication use were not collected (n=3196), patients from centers without cardiac surgery capability (n=15 155), transfer-out patients because in-hospital outcomes could not be tracked after interhospital transfer due to US privacy regulations centers (n=2498), and patients who died <24 hours of hospital admission (n=663). We further excluded patients at hospitals with a high percentage of missing bleeding events (1535 patients from 11 hospitals) and patients who had missing information on major bleeding events (n=1749). Lastly, hospitals with ≤40 NSTEMI admissions during the study period were excluded to obtain a reliable estimate of hospital bleeding rates (922 patients from 47 hospitals). After these exclusions, our study population consisted of 99 200 NSTEMI patients from 267 hospitals across the United States.
Variables of Interest
Consistent with previous ACTION Registry-GWTG studies, in-hospital major bleeding was defined as an absolute hemoglobin (Hb) drop ≥4 g/dL (initial to nadir), intracranial hemorrhage, documented or suspected retroperitoneal bleed, any RBC transfusion with baseline Hb ≥9 g/dL, or any RBC transfusion with Hb <9 g/dL and a suspected bleeding event. 8 Given that a majority of patients undergoing coronary artery bypass graft surgery receive blood transfusions related to the surgery, bleeding events were considered only if they occurred before coronary artery bypass graft surgery in those patients managed surgically.
The ACTION Registry-GWTG collects data on medications including antiplatelet and anticoagulant agents. In accordance with published guidelines and package inserts, 2,3,9-11 excess dosing was defined as follows: (1) for unfractionated heparin, an initial bolus dose >60 U/kg (max 4000 U) or initial infusion >12 U/kg per hour (max 1000 U/h); (2) for low-molecular-weight heparin (LMWH),
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WHAT THE STUDy ADDS
• In this large contemporary registry of patients with non-ST-segment elevation myocardial infarction, the authors found substantial variation among hospitals in the rates of major bleeding, with some hospitals having observed bleeding rates >2 times higher than others. • Nearly 20% of variation is attributable to patient case mix, and differences in anticoagulation and antiplatelet strategies explained an incremental 10% and 7% variation. Nearly 70% of bleeding variation remains after adjustment. • Without a better understanding of the causes of residual variation in bleeding, it would be premature to consider bleeding rates as a quality indicator. 
Statistical Analysis
For descriptive purposes, patient baseline characteristics, in-hospital treatments, and outcomes were summarized as percentage or median (interquartile range [IQR]) as appropriate and compared over quartiles of risk-adjusted hospital-level bleeding rates (described under Model 1 below) using the Mantel-Haenszel χ 2 test for categorical variables and the Kruskal-Wallis test for continuous variables. To quantify the degree to which patient case mix and treatment factors influence hospital bleeding variability, we built a series of multivariable hierarchical logistic regression models, with a random intercept for hospital. The unadjusted model contained only hospital-specific random intercepts and no covariates. Subsequent models were fit, incrementally adjusting for additional patient case mix (Model 1) and treatments (Models 2-4). Model 1 consisted of a list of patient covariates from the previously validated ACTION Registry-GWTG in-hospital major bleeding model, including age, sex, weight, diabetes mellitus, peripheral artery disease, home warfarin use, heart rate and systolic blood pressure on admission, baseline hemoglobin, baseline serum creatinine, ECG findings, and heart failure or shock on presentation. 8 Risk-adjusted in-hospital bleeding rates were calculated for each hospital using the estimated hospital-specific parameters from the respective hierarchical model (Model 1). These rates are obtained as the ratio of predicted to expected bleeding, multiplied by the overall unadjusted bleeding rate. 12 For descriptive purposes, the hospitals were further divided into quartiles based on adjusted bleeding rates.
Model 2 consisted of covariates in Model 1 plus the use of anticoagulant agents any time during hospitalization (unfractionated heparin, LMWH, bivalirudin, and fondaparinux; and excess dose of unfractionated heparin or LMWH). Model 3 consisted of covariates in Model 2 plus the use of antiplatelet agents within the first 24 hours of hospital arrival (aspirin, clopidoregl or prasugrel, glycoprotein IIb/IIIa inhibitor, and excess dose of glycoprotein IIb/IIIa inhibitor). Model 4 consisted of covariates in Model 3 plus invasive procedures during hospitalization (diagnostic catheterization, percutaneous coronary intervention [PCI]). In Models 2 to 4, the treatments and procedures were evaluated up until a bleeding event but not after. For example, PCI took a value of 1 if it occurred any time during hospitalization and before bleeding and 0 if it was never used or only after bleeding. From each sequential model, we generated an estimate of the random effect variance or variation in log-odds attributable to between-hospital differences. The proportional change in variance
where V A is variance of the initial model and V B is variance of the model with more additional covariates. 13, 14 We report estimated distribution rather than observed distribution of hospital rates of bleeding to limit sampling variation. For each set of adjustment covariates, a hierarchical model was used for estimating the distribution of hospital rates of bleeding after subtracting out the effect of random sampling variation. The log-odds for random hospital are typically assumed to be normally distributed with mean equal to the intercept and variance equal to the random effect variance. We estimated these parameters from the unadjusted model and transformed from the log-odds scale to the probability scale. Subsequently, we replaced the random effect variance with new estimates based on the adjusted models. Because this calculation is based directly on the estimated random effect variance, it provides a portrait of hospital variation that is neither excessively variable nor overshrunk. The estimated distribution of hospital-specific bleeding rates for each hospital is then overlayed on a single plot to visually represent the relative reduction in variation. All statistical analyses were performed using SAS version 9.3 software (SAS Institute, Cary, NC).
Results
Among 99 200 NSTEMI patients from 267 hospitals (median NSTEMI patients per hospital, 233; IQR, 111-509) in the ACTION Registry-GWTG, 9566 (9.6%) experienced a major bleeding event during index hospitalization. The median (IQR) of the estimated distribution of major bleeding rates among hospitals was 9.4% (7.5%-11.7%).
According to the unadjusted model, patients at hospitals in the 90th percentile of bleeding distribution were 2.3 times (14.2%/6.1%) more likely to bleed than at hospitals in the 10th percentile. Differences in patient and hospital characteristics, in-hospital treatment strategies, and outcomes by hospital-adjusted bleeding rate quartiles are illustrated in Tables 1 and 2 . Because of the large sample size, some P values may be statistically significant but of little clinical relevance. As expected, baseline patient characteristics were well balanced between the groups after case-mix adjustment ( Table 1 ). The percentage of academic hospitals increased with greater adjusted bleeding rates (10.6%, 22.4%, 28.4%, and 34.3% from quartiles 1 through 4, respectively; P<0.001). Patients at centers with high adjusted bleeding rates were more likely to receive unfractionated heparin or glycoprotein IIb/IIIa inhibitor therapy and less likely to receive LMWH or bivalirudin, when compared with patients admitted to centers with low adjusted bleeding rates (Table 2; all P<0.001). Among patients who received glycoprotein IIb/ IIIa inhibitors, unfractionated heparin, or LMWH, excess dosing occurred in 9.0% (3230 of 35 842), 63.9% (9700 of 15 179), and 8.9% (3009 of 33 930) of patients, respectively. There were no statistically significant differences in excess dosing of glycoprotein IIb/IIIa inhibitor between groups. There were only modest differences in excess dosing of unfractionated heparin or LMWH. Similarly, there were no statistically significant differences in the use of PCI and only modest differences in the use of diagnostic catheterization or coronary artery bypass graft surgery. Patients treated in hospitals with higher bleeding quartiles also have higher transfusion rates and longer length of stay compared with patients in centers with lower adjusted bleeding quartiles.
We built a series of multivariable hierarchical logistic regression models to quantify the degree to which patient case-mix and treatment factors influence variability in hospital bleeding. Figure 2 shows the estimated distribution of hospital bleeding rates corresponding to each sequential model. A 19.2% reduction in PCV was observed when comparing the case mix adjusted Model 1 to the unadjusted model. Antithrombotic strategies explained an additional 16.0% reduction in bleeding variation. Together, 32.3% hospital variation in major bleeding rates was attributable to identifiable differences in patient case mix and differences in treatment strategies. The incremental PCV of specific treatment strategies was described in Table 3 . Incremental reductions in bleeding variation were observed after adjusting for anticoagulation (9.9%) and antiplatelet strategy (6.8%). Meanwhile, differences in diagnostic cardiac catheterization and PCI only contributed 0.2% incremental reductions in bleeding variation after accounting for antithrombotic strategies. In a sensitivity analysis performed by reversing the order of the covariates entering into the model (case mix followed by invasive procedures), differential use of diagnostic cardiac catheterization and PCI only contributed 0.5% incremental reductions in hospital bleeding variations.
Discussion
In this large contemporary registry of patients with NSTEMI, we found substantial variation among hospitals in the rates of major bleeding, with some hospitals having observed bleeding rates >2 times higher than in others. Patient case mix and antithrombotic strategies were associated with bleeding; they contributed 19.2% and 16.0% of hospital-level variation in major bleeding, respectively. Nearly 70% of variation in bleeding among hospitals remains after controlling for case mix and observed differences in treatment strategies. Although unmeasured confounders certainly remain, this finding highlights an opportunity for observed care variation to be a tool to CABG indicates coronary artery bypass graft; GP, glycoprotein; LMWH, low-molecular-weight heparin; PCI, percutaneous coronary intervention; Q, quartile; RBC, red blood cell; and UFH, unfractionated heparin. *Adjustment for patient-level characteristics at the time of initial hospital presentation, including age, sex, weight, diabetes mellitus, peripheral artery disease, home warfarin use, heart rate on admission, systolic blood pressure on admission, baseline hemoglobin, baseline serum creatinine, ECG findings, heart failure or shock on presentation.
†Median (interquartile range) or percentage. ‡Excess dose of GP IIb/IIIa inhibitor was defined as failure to appropriately reduce doses for creatinine clearance. For eptifibatide, full-dose infusion was defined as 2 μg/kg per min, with reduced dose of 1 μg/kg per min for patients with creatinine clearance <50 mL/min or on dialysis. For tirofiban, full-dose infusion was defined as 0.1 μg/kg per min, with reduced dose of 0.05 μg/kg per min for patients with creatinine clearance <30 mL/min or on dialysis. Creatinine clearance was estimated using the Cockcroft-Gault equation.
§Excess dose of UFH was defined as a bolus dose >60 U/kg (max 4000 U) or infusion >12 U/kg per h (max 1000 U/h). ‖Excess dose of LMWH was defined as enoxaparin daily dose exceeded the recommended daily dose by >10 mg over a total daily dose of 2 mg/kg for patients with creatinine clearance ≥30 mL/min, or 1 mg/kg for patients with creatinine clearance <30 mL/min or on dialysis.
#Major bleeding was defined as an absolute hemoglobin (Hb) drop ≥4 g/dL (initial to nadir), intracranial hemorrhage, documented or suspected retroperitoneal bleed, any RBC transfusion with baseline Hb ≥9 g/dL, or any RBC transfusion with Hb <9 g/dL and a suspected bleeding event. Bleeding events were considered only if they occurred before CABG.
identify practices, which limit bleeding complications during NSTEMI care.
Improving hospital safety has been identified as a national priority in promoting high-quality care. 15 Consistent with previous reports of wide variation in bleeding complications in clinical trials and in community practice, 1,2,16 we found major bleeding rates variability among reporting centers, suggesting the potential to prevent bleeding events by improving quality of care rendered by hospitals. Because differences in bleeding rates among hospitals can be attributable to case mix, and evidence-based treatments are known to contribute to bleeding, a fair comparison for hospital major bleeding complications remains a challenge. Incorporating a validated bleeding risk model, we removed the contribution of measured patient characteristics present at the time of initial treatments and specifically examined the source of variation to identifiable differences in treatment strategies. Although the 19.2% due to case mix is not actionable, the 16% variation attributed to treatment strategies after case-mix adjustment may represent a potential target for quality improvement efforts. Exploring the healthcare practices at centers with high and low bleeding rates may identify new avenues to improve the safe delivery of care.
Antithrombotic therapy has become the standard treatment for patients with acute myocardial infarction. Current guidelines recommend concomitant antithrombotic therapy including aspirin, P2Y12 receptor inhibitors, glycoprotein IIb/IIIa inhibitors, unfractionated heparin, LMWH, or bivalirudin coupled with early invasive procedures. 17, 18 Although these therapies can be life-saving and reduce patients' likelihood of recurrent ischemic events, the use of antithrombotic therapy can also put patients at risk for bleeding events, which might partially explain the larger portion of academic centers with higher adjusted bleeding rates in our study. Results from randomized clinical trials have demonstrated lower risk of bleeding with bivalirudine use as compared with heparin plus glycoprotein IIb/IIIa inhibitors. [19] [20] [21] [22] Similarly, we found high rates of unfractionated heparin and glycoprotein IIb/IIIa inhibitors use and low rates of LMWH and bivalirudin use in centers with high adjusted bleeding rates, suggesting that differential use of antithrombotic agents may have contributed to bleeding variations in these hospitals. Furthermore, knowing the patients' bleeding risk can impact physician behavior in terms of treatment used. 23 Although we did not examine the relationship between individual bleeding risk profile and treatment selection with our current study design, we found that these factors together explained 32.3% hospital variation in major bleeding rates. Therefore, defining optimal treatment selection based on risk factors might be a critical step to motivate appropriate use of antithrombotic treatments and further reduce bleeding complications.
Although it is expected that greater use of diagnostic catheterization and PCI would increase the risk of major bleeding, after accounting for case mix and antithrombotic strategies, invasive procedures were only minimally associated with variations in bleeding. These results might be attributable to the consistently high use of invasive procedures in our patient population. We limited our analysis to hospitals with cardiac surgery capability, and ≈80% of patients underwent diagnostic catheterization, Table 3 Table 2 for bleeding and excess dosing definitions.
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Figure 2.
Estimated distribution of hospital-specific bleeding rates. The y axis is labeled density, which implies that the graph is a smoothed histogram with area under the curve of 1, so that the area between any 2 points on the x axis represents the proportion of hospitals within that range. and nearly half of the patients underwent PCI. Furthermore, given the correlation between antithrombotic therapy and catheter-based procedures, the influence of invasive procedures on bleeding might have already been accounted for by considering antithrombotic treatments. Regardless, we conducted sensitivity analyses in which the sequence of inclusion for treatment strategies was changed and found consistent results. Nonetheless, 70% of variation in bleeding among hospitals remains even after adjustment. Possible explanations for this large residual variation include unmeasured patient risk factors (eg, gastrointestinal ulcers, vascular fragility, frailty) as well as potential differences in the process of care (eg, use of fluoroscopy or ultrasound to guide arterial access, postcatheterization management, timing or duration of antithrombotic therapy). There were more patients on dialysis in high bleeding centers, emphasizing the contribution of advanced comorbidity. Higher bleeding quartiles also demonstrated longer stays, perhaps a result of bleeding events or reflecting initial hospital care and prolonged exposure to anticoagulants. Furthermore, we were unable to evaluate the use of bleeding avoidance strategies in the ACTION Registry-GWTG database; this could be important because several recent studies suggest that vascular closure devices and radial artery catheterization reduce major bleeding after PCI. [24] [25] [26] Without a clear understanding of the residual causes of variation in bleeding, reporting bleeding rates as a quality indicator would be premature. Quality measures might misalign incentives and lead to unintended consequences, especially for hospitals that manage high-risk patients. 27, 28 
Limitations
Our study should be interpreted in the context of the following limitations. The study is retrospective and based on registry data and, therefore, includes the inherent limitations of those methods. Although we found that antithrombotic strategies can contribute to a marked variation in hospital major bleeding rates even after adjustment for patient case mix, a causal relationship cannot be concluded. Second, the extent to which a covariate accounts for variation does not reflect its importance for explaining outcome. Nevertheless, variation is a summary measure of hospital differences, and we were able to explore the relative contribution of known factors. Third, we were unable to determine the optimal agent, dose, and timing of initiation of antithrombotic therapy in our current study design. Regardless, numerous studies and published guidelines have helped define antiplatelet or anticoagulant strategies for the management of patients with STEMI, NSTEMI, and unstable angina. 16, 17 Finally, although we attempted to address hospital bleeding variation by adjusting for a broad range of patient-level clinical factors and treatments, the possibility of confounding by unmeasured covariates remains.
Conclusions
In summary, we found substantial hospital variation in major bleeding rates in the contemporary treatment of NSTEMI. More than two thirds of the variation persists after accounting for patients' case mix and observed differences in treatment strategies. Although we were unable to account for the majority of observed hospital variation, differential uses of anticoagulant and antiplatelet agent explain 16% of variation in hospital-adjusted major bleeding rates. A better understanding of etiologies of hospital variation in bleeding complications may help institutions target high-risk patients and provide optimal care in this population.
